| Literature DB >> 30496704 |
Silvia González-Ramos1,2, Marta Paz-García1,2, Cristina Rius3, Alberto Del Monte-Monge2,3, Cristina Rodríguez2,4, Victoria Fernández-García1,2, Vicente Andrés2,3, José Martínez-González2,5, Miguel A Lasunción6, Paloma Martín-Sanz1,2, Oliver Soehnlein7,8,9, Lisardo Boscá1,2.
Abstract
Atherosclerosis is a chronic disease characterized by vascular lipid retention and inflammation, and pattern recognition receptors (PRRs) are important contributors in early stages of the disease. Given the implication of the intracellular PRR nucleotide-binding oligomerization domain 1 (NOD1) in cardiovascular diseases, we investigated its contribution to early atherosclerosis. We evidenced NOD1 induction in atherosclerotic human and mouse tissues, predominantly in vascular endothelial cells. Accordingly, NOD1 genetic inactivation in Apoe-/- mice reduced not only atherosclerosis burden, but also monocyte and neutrophil accumulation in atheromata. Of note, in the presence of either peptidoglycan or oxidized LDLs, endothelial NOD1 triggered VCAM-1 up-regulation through the RIP2-NF-κB axis in an autocrine manner, enhancing firm adhesion of both sets of myeloid cells to the inflamed micro- and macrovasculature in vivo. Our data define a major proatherogenic role for endothelial NOD1 in early leukocyte recruitment to the athero-prone vasculature, thus introducing NOD1 as an innovative therapeutic target and potential prognostic molecule.-González-Ramos, S., Paz-García, M., Rius, C., del Monte-Monge, A., Rodríguez, C., Fernández-García, V., Andrés, V., Martínez-González, J., Lasunción, M. A., Martín-Sanz, P., Soehnlein, O., Boscá, L. Endothelial NOD1 directs myeloid cell recruitment in atherosclerosis through VCAM-1.Entities:
Keywords: cardiovascular disease; innate immunity; leukocyte
Year: 2018 PMID: 30496704 DOI: 10.1096/fj.201801231RR
Source DB: PubMed Journal: FASEB J ISSN: 0892-6638 Impact factor: 5.191